source
- Regulatory experts urge risk-based, lifecycle validation for AI tools in FDA workAt the RAPS AI in Regulatory Conference in Barcelona, a panel of experts discussed the growing use of AI tools by regulatory professionals. They recommended a risk-based, lifecycle approach to val…
- RevMed's pancreatic cancer drug Rasonque generates $198M in Q3, far exceeding forecastsRevMed reported $198 million in revenue from its newly launched pancreatic cancer therapy Rasonque during the third quarter, roughly ten times the $19 million estimate from Truist Securities. The…